Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 9/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 9/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 9/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 9/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 9/20 | 0.46 |
| ▸ | EED | O75530 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702143 | 0.84 | GRIN2D (0.70) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL563657 | 0.80 | GRIN2D (0.69) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL8800979 | 0.78 | GRIN2D (0.67) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL8112333 | 0.78 | GRIN2D (0.67) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL17005777 | 0.78 | GRIN2D (0.70) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL692976 | 0.78 | EED (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL692848 | 0.72 | GRIN2D (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL578027 | 0.69 | MAOA (0.59) | CHRM1ADRA1A | |
| SCHEMBL8260850 | 0.69 | GRIN2D (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29500303 | 0.69 | DRD1 (0.56) | MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | claimed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | claimed |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-28 | — | — | US | claimed |
| US-8445477-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-21 | — | — | US | claimed |
| EP-2421823-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124086-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | disclosed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | disclosed |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-28 | — | — | US | disclosed |
| US-8445477-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-21 | — | — | US | disclosed |
| EP-2421823-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | disclosed |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| WO-2010124086-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | GRIN2D 3207/4885GRIN3B 3966/4885GRIN1 2360/4885 |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | GRIN2D 3207/4885GRIN3B 3966/4885GRIN1 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.